Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

Inclusion Criteria: * Participants must have an LDL-C concentration \>= 3.3 mmol/L (130 mg/dL) to \<= 4.9 mmol/L (190 mg/dL) using the Freidewald calculation. * Participants must have triglyceride concentrations of \< 3.99 mmol/L (350 mg/dL). * Participants must have two or more coronary heart disease risk factors listed below: * Current cigarette smoking * Hypertension (BP \>= 140/90 mmHg or on antihypertensive medication) * Low HDL cholesterol (\< 40 mg/dL) * Family history of premature CHD (CHD in male first degree relative \< 55 years; CHD in female first degree relative \< 65 years) * Age (Men \>= 45 years; women \>= 55 years) * Participant must be currently taking atorvastatin 10 mg daily and by history has taken 80% of daily doses for the 6 weeks prior to participating. * Participants must have liver transaminases (ALT, AST) \< 50% above the upper limit of normal, with no active liver disease, and CK \< 50% above the upper limit of normal. * Participants must have maintained a cholesterol lowering diet, exercise program, and stable weight for at least 4 weeks prior to the study and be willing to continue the same diet and exercise program during the study. * Women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives, must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the duration of the study. Exclusion Criteria: * Partici…